TRERF1 and non-small cell lung carcinoma: The results provided evidence of cell level of the combination of Rapa and Osi in the treatment of NSCLC and an important theoretical basis for clinical practice, but the clinical application needs to further consider dose optimization, patient-specific factors, and combination therapy strategies.